Zepp Health (ZEPP) Research & Development (2016 - 2026)

Zepp Health (ZEPP) has reported Research & Development for 11 consecutive years, with -$13.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development fell 6.12% year-over-year to -$13.1 million; the TTM figure through Mar 2026 stood at -$46.1 million (down 2.13% YoY), while the FY2025 annual figure was $45.3 million, down 1.82% from the prior year.
• Research & Development came in at -$13.1 million for Q1 2026 at Zepp Health, down from -$11.0 million in the prior quarter.
• The five-year high for Research & Development was -$10.4 million in Q3 2023, with the low at -$23.1 million in Q1 2022.
• Average Research & Development over 5 years is -$13.7 million, with a median of -$12.4 million recorded in 2025.
• Across the five-year window, Research & Development plunged 199.33% in 2022 and jumped 42.12% in 2023, its largest moves.
• Year by year, Research & Development stood at -$16.6 million in 2022, then surged by 32.9% to -$11.1 million in 2023, then climbed by 0.57% to -$11.1 million in 2024, then climbed by 0.71% to -$11.0 million in 2025, then fell by 19.6% to -$13.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered -$13.1 million, -$11.0 million, and -$10.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.